Maria Kokkini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Kokkini has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Oves-Costales
Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Parque Tecnológico Ciencias de la Salud, Avda. del Conocimiento 34, 18016 Armilla, Granada, Spain
3 shared publications - Fernando Reyes
Fundación MEDINA, Granada, Spain
3 shared publications - Francisca Vicente
Fundación MEDINA, Avda Conocimiento 34, 18016 Granada, Spain
3 shared publications - Jesús Martín
Fundación MEDINA, Granada, Spain
3 shared publications - Olga Genilloud
Fundación Medina, Granada, Spain, Spain
3 shared publications - Mercedes Pérez-Bonilla
Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Parque Tecnológico Ciencias de la Salud, Avda. del Conocimiento 34, 18016 Armilla, Granada, Spain
2 shared publications
Latest Publications
- Open Access
- 7 August 2023
- Published by MDPI AG in Marine Drugs
- Vol. 21 (8) , 443
New Phocoenamicin and Maklamicin Analogues from Cultures of Three Marine-Derived Micromonospora Strains
Antimicrobial resistance can be considered a hidden global pandemic and research must be reinforced for the discovery of new antibiotics. The spirotetronate class of polyketides, with more than 100 bioactive compounds described to date, has recently grown with the discovery of phocoenamicins, compounds displaying different antibiotic activities. Three marine Micromonospora strains (CA-214671, CA-214658 and CA-218877), identified as phocoenamicins producers, were chosen to scale up their production and LC/HRMS analyses proved that EtOAc extracts from their culture broths produce several structurally related compounds not disclosed before. Herein, we report the production, isolation and structural elucidation of two new phocoenamicins, phocoenamicins D and E (1–2), along with the known phocoenamicin, phocoenamicins B and C (3–5), as well as maklamicin (7) and maklamicin B (6), the latter being reported for the first time as a natural product. All the isolated compounds were tested against various human pathogens and revealed diverse strong to negligible activity against methicillin-resistant Staphylococcus aureus, Mycobacterium tuberculosis H37Ra, Enterococcus faecium and Enterococcus faecalis. Their cell viability was also evaluated against the human liver adenocarcinoma cell line (Hep G2), demonstrating weak or no cytotoxicity. Lastly, the safety of the major compounds obtained, phocoenamicin (3), phocoenamicin B (4) and maklamicin (7), was tested against zebrafish eleuthero embryos and all of them displayed no toxicity up to a concentration of 25 μM.
- 7 August 2023
- Published by MDPI AG in Marine Drugs
- Vol. 21 (8) , 443
Open AccessNew Phocoenamicin and Maklamicin Analogues from Cultures of Three Marine-Derived Micromonospora Strains
Antimicrobial resistance can be considered a hidden global pandemic and research must be reinforced for the discovery of new antibiotics. The spirotetronate class of polyketides, with more than 100 bioactive compounds described to date, has recently grown with the discovery of phocoenamicins, compounds displaying different antibiotic activities. Three marine Micromonospora strains (CA-214671, CA-214658 and CA-218877), identified as phocoenamicins producers, were chosen to scale up their production and LC/HRMS analyses proved that EtOAc extracts from their culture broths produce several structurally related compounds not disclosed before. Herein, we report the production, isolation and structural elucidation of two new phocoenamicins, phocoenamicins D and E (1–2), along with the known phocoenamicin, phocoenamicins B and C (3–5), as well as maklamicin (7) and maklamicin B (6), the latter being reported for the first time as a natural product. All the isolated compounds were tested against various human pathogens and revealed diverse strong to negligible activity against methicillin-resistant Staphylococcus aureus, Mycobacterium tuberculosis H37Ra, Enterococcus faecium and Enterococcus faecalis. Their cell viability was also evaluated against the human liver adenocarcinoma cell line (Hep G2), demonstrating weak or no cytotoxicity. Lastly, the safety of the major compounds obtained, phocoenamicin (3), phocoenamicin B (4) and maklamicin (7), was tested against zebrafish eleuthero embryos and all of them displayed no toxicity up to a concentration of 25 μM.
- Open Access
- 7 December 2022
- Published by MDPI AG in Marine Drugs
- Vol. 20 (12) , 769
Exploring Micromonospora as Phocoenamicins Producers
Over the past few years, new technological and scientific advances have reinforced the field of natural product discovery. The spirotetronate class of natural products has recently grown with the discovery of phocoenamicins, natural actinomycete derived compounds that possess different antibiotic activities. Exploring the MEDINA’s strain collection, 27 actinomycete strains, including three marine-derived and 24 terrestrial strains, were identified as possible phocoenamicins producers and their taxonomic identification by 16S rDNA sequencing showed that they all belong to the Micromonospora genus. Using an OSMAC approach, all the strains were cultivated in 10 different media each, resulting in 270 fermentations, whose extracts were analyzed by LC-HRMS and subjected to High-throughput screening (HTS) against methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium tuberculosis H37Ra and Mycobacterium bovis. The combination of LC-UV-HRMS analyses, metabolomics analysis and molecular networking (GNPS) revealed that they produce several related spirotetronates not disclosed before. Variations in the culture media were identified as the most determining factor for phocoenamicin production and the best producer strains and media were established. Herein, we reported the chemically diverse production and metabolic profiling of Micromonospora sp. strains, including the known phocoenamicins and maklamicin, reported for the first time as being related to this family of compounds, as well as the bioactivity of their crude extracts. Although our findings do not confirm previous statements about phocoenamicins production only in unique marine environments, they have identified marine-derived Micromonospora species as the best producers of phocoenamicins in terms of both the abundance in their extracts of some major members of the structural class and the variety of molecular structures produced.
- 7 December 2022
- Published by MDPI AG in Marine Drugs
- Vol. 20 (12) , 769
Open AccessExploring Micromonospora as Phocoenamicins Producers
Over the past few years, new technological and scientific advances have reinforced the field of natural product discovery. The spirotetronate class of natural products has recently grown with the discovery of phocoenamicins, natural actinomycete derived compounds that possess different antibiotic activities. Exploring the MEDINA’s strain collection, 27 actinomycete strains, including three marine-derived and 24 terrestrial strains, were identified as possible phocoenamicins producers and their taxonomic identification by 16S rDNA sequencing showed that they all belong to the Micromonospora genus. Using an OSMAC approach, all the strains were cultivated in 10 different media each, resulting in 270 fermentations, whose extracts were analyzed by LC-HRMS and subjected to High-throughput screening (HTS) against methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium tuberculosis H37Ra and Mycobacterium bovis. The combination of LC-UV-HRMS analyses, metabolomics analysis and molecular networking (GNPS) revealed that they produce several related spirotetronates not disclosed before. Variations in the culture media were identified as the most determining factor for phocoenamicin production and the best producer strains and media were established. Herein, we reported the chemically diverse production and metabolic profiling of Micromonospora sp. strains, including the known phocoenamicins and maklamicin, reported for the first time as being related to this family of compounds, as well as the bioactivity of their crude extracts. Although our findings do not confirm previous statements about phocoenamicins production only in unique marine environments, they have identified marine-derived Micromonospora species as the best producers of phocoenamicins in terms of both the abundance in their extracts of some major members of the structural class and the variety of molecular structures produced.
- Open Access
- 16 March 2018
- Published by MDPI AG in Marine Drugs
- Vol. 16 (3) , 95
Phocoenamicins B and C, New Antibacterial Spirotetronates Isolated from a Marine Micromonospora sp.
Phocoenamicins B and C (1 and 2), together with the known spirotetronate phocoenamicin (3), were isolated from cultures of Micromonospora sp. The acetone extract from a culture of this strain, isolated from marine sediments collected in the Canary Islands, displayed activity against methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium tuberculosis H37Ra and Mycobacterium bovis. Bioassay-guided fractionation of this extract using SP207ss column chromatography and preparative reversed-phased HPLC led to the isolation of the new compounds 1 and 2 belonging to the spirotetronate class of polyketides. Their structures were determined using a combination of HRMS, 1D and 2D NMR experiments and comparison with the spectra reported for phocoenamicin. Antibacterial activity tests of the pure compounds against these pathogens revealed minimal inhibitory concentration (MIC) values ranging from 4 to 64 µg/mL for MRSA, and 16 to 32 µg/mL for M. tuberculosis H37Ra, with no significant activity found against M. bovis and vancomycin-resistant Enterococcus faecium (VRE) at concentrations below 128 µg/mL, and weak activity detected against Bacillus subtilis grown on agar plates.
- 16 March 2018
- Published by MDPI AG in Marine Drugs
- Vol. 16 (3) , 95
Open AccessPhocoenamicins B and C, New Antibacterial Spirotetronates Isolated from a Marine Micromonospora sp.
Phocoenamicins B and C (1 and 2), together with the known spirotetronate phocoenamicin (3), were isolated from cultures of Micromonospora sp. The acetone extract from a culture of this strain, isolated from marine sediments collected in the Canary Islands, displayed activity against methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium tuberculosis H37Ra and Mycobacterium bovis. Bioassay-guided fractionation of this extract using SP207ss column chromatography and preparative reversed-phased HPLC led to the isolation of the new compounds 1 and 2 belonging to the spirotetronate class of polyketides. Their structures were determined using a combination of HRMS, 1D and 2D NMR experiments and comparison with the spectra reported for phocoenamicin. Antibacterial activity tests of the pure compounds against these pathogens revealed minimal inhibitory concentration (MIC) values ranging from 4 to 64 µg/mL for MRSA, and 16 to 32 µg/mL for M. tuberculosis H37Ra, with no significant activity found against M. bovis and vancomycin-resistant Enterococcus faecium (VRE) at concentrations below 128 µg/mL, and weak activity detected against Bacillus subtilis grown on agar plates.
- Open Access
- 8 October 2016
- Published by Enviro Research Publishers in Current Research in Nutrition and Food Science Journal
- Vol. 4 (Special--O) , 152-160
Determination of Α- and Β-Thujone in Wormwood and Sage Infusions of Greek Flora and Estimation of their Average Toxicity
Artemisia absinthium (wormwood) and Salvia sp. (sage) are used as additives to pharmaceuticals, food and alcoholic beverages while in Greece both herbs are also consumed as infusions. The compounds α- and β-thujone, are monoterpenes, which are found in various preparations of these herbs. According to organizations (EMA, SCF) and clinical studies, α- and β-thujone have shown neurotoxic effects in humans over established limits. In this study wormwoodandsageinfusions were investigated in terms of the relative % content of the volatile constituents and the concentrations of α- and β-thujone by gas chromatography-mass spectrometry (GC-MS). In sage infusions, α-thujone was the predominant isomer while in wormwood β-thujone was dominated. Our results revealed that most of the above herbal infusions exceed thujone limits as set by EMA, which are 3 mg/day for wormwood and 5 mg/day for sage. Furthermore, the average toxicity as performed by the Microtox® Analyzer showed higher levels of toxicity in sage infusions compared to the wormwood. No correlation was found between thujone content and toxicity levels of both sage and wormwood infusions.
- 8 October 2016
- Published by Enviro Research Publishers in Current Research in Nutrition and Food Science Journal
- Vol. 4 (Special--O) , 152-160
Open AccessDetermination of Α- and Β-Thujone in Wormwood and Sage Infusions of Greek Flora and Estimation of their Average Toxicity
Artemisia absinthium (wormwood) and Salvia sp. (sage) are used as additives to pharmaceuticals, food and alcoholic beverages while in Greece both herbs are also consumed as infusions. The compounds α- and β-thujone, are monoterpenes, which are found in various preparations of these herbs. According to organizations (EMA, SCF) and clinical studies, α- and β-thujone have shown neurotoxic effects in humans over established limits. In this study wormwoodandsageinfusions were investigated in terms of the relative % content of the volatile constituents and the concentrations of α- and β-thujone by gas chromatography-mass spectrometry (GC-MS). In sage infusions, α-thujone was the predominant isomer while in wormwood β-thujone was dominated. Our results revealed that most of the above herbal infusions exceed thujone limits as set by EMA, which are 3 mg/day for wormwood and 5 mg/day for sage. Furthermore, the average toxicity as performed by the Microtox® Analyzer showed higher levels of toxicity in sage infusions compared to the wormwood. No correlation was found between thujone content and toxicity levels of both sage and wormwood infusions.